On Tuesday, Fate Therapeutics Inc (NASDAQ: FATE) was -4.05% drop from the session before settling in for the closing price of $0.94. A 52-week range for FATE has been $0.87 – $7.65.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 46.37% over the last five years. When this article was written, the company’s average yearly earnings per share was at 4.69%. With a float of $103.48 million, this company’s outstanding shares have now reached $113.93 million.
The firm has a total of 181 workers. Let’s measure their productivity. In terms of profitability, gross margin is -189.23%, operating margin of -1542.63%, and the pretax margin is -1366.46%.
Fate Therapeutics Inc (FATE) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Fate Therapeutics Inc stocks. The insider ownership of Fate Therapeutics Inc is 9.70%, while institutional ownership is 85.14%. The most recent insider transaction that took place on Mar 06 ’25, was worth 104,881. Before that another transaction happened on Jan 10 ’25, when Company’s insider sold 5,980 for $1.55, making the entire transaction worth $9,269. This insider now owns 270,203 shares in total.
Fate Therapeutics Inc (FATE) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.44% during the next five years compared to -2.63% drop over the previous five years of trading.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
You can see what Fate Therapeutics Inc (FATE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.65, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Analysing the last 5-days average volume posted by the [Fate Therapeutics Inc, FATE], we can find that recorded value of 1.26 million was lower than the volume posted last year of 2.35 million. As of the previous 9 days, the stock’s Stochastic %D was 31.28%. Additionally, its Average True Range was 0.10.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 1.24%, which indicates a significant decrease from 17.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.60% in the past 14 days, which was lower than the 106.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1961, while its 200-day Moving Average is $2.6924. Now, the first resistance to watch is $0.9377. This is followed by the second major resistance level at $0.9727. The third major resistance level sits at $0.9958. If the price goes on to break the first support level at $0.8796, it is likely to go to the next support level at $0.8565. Now, if the price goes above the second support level, the third support stands at $0.8215.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
There are 114,597K outstanding shares of the company, which has a market capitalization of 103.45 million. As of now, sales total 13,630 K while income totals -186,260 K. Its latest quarter income was 1,860 K while its last quarter net income were -52,150 K.
